First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis

Guiyuan Xiang, Yue-Yue Huang, Ni Zhang, Xinyu Du, Yuanlin Wu, Lanlan Gan, Yanping Li, Tingting Jiang, Yao LiuClinical 2024 · DOI

Abstract

At a willingness-to-pay threshold of US$36 780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.
BibTeX
@inproceedings{xiang2024first,
  author = {Guiyuan Xiang and Yue-Yue Huang and Ni Zhang and Xinyu Du and Yuanlin Wu and Lanlan Gan and Yanping Li and Tingting Jiang and Yao Liu},
  title = {{First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1177/11795549241299393},
}

Loading related content...

Figure